NCT06294912

A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)

A Controlled Human Malaria Infection Study to Evaluate the Antimalarial Activity of MK-7602 Against Plasmodium Falciparum Blood Stage Infection in Healthy Adult Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess the antimalarial activity, pharmacokinetics, and safety of MK-7602 in healthy adults following Plasmodium falciparum (P. falciparum) infection.

Conditions

• Malaria

Interventions

Type	Name	Description
OTHER	Plasmodium falciparum	Parasite inoculation administered by intravenous (IV) infusion as the challenge agent
DRUG	MK-7602	Capsules to be administered orally.
DRUG	Artemether/lumefantrine	Tablets to be administered orally as definitive antimalarial treatment.
DRUG	Primaquine	Tablets to be administered orally as definitive antimalarial treatment.
DRUG	Artesunate	Intravenous (IV) infusion to be administered as definitive antimalarial treatment.
DRUG	Atovaquone/proguanil	Tablets to be administered orally as definitive antimalarial treatment.

Timeline

• Start date: 2024-04-18
• Primary completion: 2025-01-06
• Completion: 2025-01-06
• First posted: 2024-03-06
• Last updated: 2025-01-13

Locations

1 site across 1 country: Australia